Genome Biologics Overview

  • Year Founded
  • 2016

Year Founded

  • Status
  • Private

  • Employees
  • 12

Employees

  • Latest Deal Type
  • Later Stage VC

  • Investors
  • 3

Genome Biologics General Information

Description

Operator of a Biotherapeutics platform intended to facilitate efficient and ethical drug development and positioning. The company's platform leverages the power of AI-based machine learning with a transformative single-cell in vitro and in vivo transgenesis to identify new compounds or to repurpose known compounds for the treatment of cardiovascular and cardiometabolic and cancer, enabling medical researchers to reduce the cost, time and ethical burden of preclinical research.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Discovery Tools (Healthcare)
Drug Discovery
Other Healthcare Technology Systems
Corporate Office
  • Centre for Molecular Medicine, Goethe-University Frankfurt
  • Theodor-Stern-Kai 7
  • 60590 Frankfurt
  • Germany
+49 069 000000000

Genome Biologics Timeline

2021202220232024
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Genome Biologics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Later Stage VC 01-Jan-2023 000.00 Completed Generating Revenue
4. Later Stage VC 20-Dec-2021 000.00 000.00 Completed Pre-Clinical Trials
3. Grant 31-Aug-2021 00.000 Completed Pre-Clinical Trials
2. Grant 09-Apr-2018 $61.6K Completed Pre-Clinical Trials
1. Accelerator/Incubator 23-Mar-2018 Completed Pre-Clinical Trials
To view Genome Biologics’s complete valuation and funding history, request access »

Genome Biologics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a Biotherapeutics platform intended to facilitate efficient and ethical drug development and positioning. Th
Biotechnology
Frankfurt, Germany
12 As of 2022
000.00
0000000000 0 000.00

000000

, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dol
0000 000000000
Oxford, United Kingdom
000 As of 0000
00000
000000000 00000

000000

s aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fug
0000 000000000
London, United Kingdom
000 As of 0000
00000
00.000 0000-00-00
000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Genome Biologics Competitors (3)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Exscientia Formerly VC-backed Oxford, United Kingdom 000 00000 000000000 00000
BenevolentAI Formerly PE-Backed London, United Kingdom 000 00000 000000000 00000
Tenaya Therapeutics Formerly VC-backed South San Francisco, CA 000 00000 00000000 00000
You’re viewing 3 of 3 competitors. Get the full list »

Genome Biologics Patents

Genome Biologics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4215195-A1 Lanatoside c, clopidogrel, and r406 in treatment of cvd-clonal hematopoiesis of indeterminate potential (cvd-chip) Inactive 19-Jan-2022 00000000000 0
US-20240110155-A1 A dual cardiac-blood model system for disease modelling and drug screening Pending 17-Dec-2020 0000000000
US-20240018478-A1 Self-organised human cardiac organoid Pending 07-Dec-2020 0000000000
US-20220332845-A1 Inhibition of mthfd1l for use in hypertrophic heart disease and heart failure Pending 05-Sep-2019 000000000
US-20220275336-A1 Method for generating cardiac tissue mimetics Pending 12-Jul-2019 C12N5/0657
To view Genome Biologics’s complete patent history, request access »

Genome Biologics Executive Team (3)

Name Title Board Seat
Jonathan Ward Co-Founder & Chief Executive Officer
Maria Duda Ph.D Chief Operating Officer
Jaya Krishnan Ph.D Co-Founder & Chief Technology Officer
To view Genome Biologics’s complete executive team members history, request access »

Genome Biologics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Genome Biologics Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds
CARMA FUND Management Venture Capital Minority 000 0000 000000 0
Horizon 2020 SME Instrument Government 000 0000 000000 0
Johnson & Johnson Innovation - JLABS Accelerator/Incubator 000 0000 000000 0
To view Genome Biologics’s complete investors history, request access »

Genome Biologics FAQs

  • When was Genome Biologics founded?

    Genome Biologics was founded in 2016.

  • Who is the founder of Genome Biologics?

    Jonathan Ward and Jaya Krishnan Ph.D are the founders of Genome Biologics.

  • Who is the CEO of Genome Biologics?

    Jonathan Ward is the CEO of Genome Biologics.

  • Where is Genome Biologics headquartered?

    Genome Biologics is headquartered in Frankfurt, Germany.

  • What is the size of Genome Biologics?

    Genome Biologics has 12 total employees.

  • What industry is Genome Biologics in?

    Genome Biologics’s primary industry is Biotechnology.

  • Is Genome Biologics a private or public company?

    Genome Biologics is a Private company.

  • What is Genome Biologics’s current revenue?

    The current revenue for Genome Biologics is 000000.

  • How much funding has Genome Biologics raised over time?

    Genome Biologics has raised $11.1M.

  • Who are Genome Biologics’s investors?

    CARMA FUND Management, Horizon 2020 SME Instrument, and Johnson & Johnson Innovation - JLABS have invested in Genome Biologics.

  • Who are Genome Biologics’s competitors?

    Exscientia, BenevolentAI, and Tenaya Therapeutics are competitors of Genome Biologics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »